<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34140581</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>GLT1 gene delivery based on bone marrow-derived cells ameliorates motor function and survival in a mouse model of ALS.</ArticleTitle><Pagination><StartPage>12803</StartPage><MedlinePgn>12803</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">12803</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-92285-x</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an intractable neurodegenerative disease. CD68-positive bone marrow (BM)-derived cells (BMDCs) accumulate in the pathological lesion in the SOD1(G93A) ALS mouse model after BM transplantation (BMT). Therefore, we investigated whether BMDCs can be applied as gene carriers for cell-based gene therapy by employing the accumulation of BMDCs. In ALS mice, YFP reporter signals were observed in 12-14% of white blood cells (WBCs) and in the spinal cord via transplantation of BM after lentiviral vector (LV) infection. After confirmation of gene transduction by LV with the CD68 promoter in 4-7% of WBCs and in the spinal cord of ALS mice, BM cells were infected with LVs expressing glutamate transporter (GLT) 1 that protects neurons from glutamate toxicity, driven by the CD68 promoter, which were transplanted into ALS mice. The treated mice showed improvement of motor behaviors and prolonged survival. Additionally, interleukin (IL)-1&#x3b2; was significantly suppressed, and IL-4, arginase 1, and FIZZ were significantly increased in the mice. These results suggested that GLT1 expression by BMDCs improved the spinal cord environment. Therefore, our gene therapy strategy may be applied to treat neurodegenerative diseases such as ALS in which BMDCs accumulate in the pathological lesion by BMT.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohashi</LastName><ForeName>Natsuko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terashima</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan. tom@belle.shiga-med.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katagi</LastName><ForeName>Miwako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakae</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Shiga University of Medical Science, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Yoshihisa</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Plastic and Reconstructive Surgery, Shiga University of Medical Science, Shiga, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Hideto</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Stem Cell Biology and Regenerative Medicine, Shiga University of Medical Science, Seta Tsukinowa-Cho, Otsu, Shiga, 520-2192, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D027342">Excitatory Amino Acid Transporter 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493396">Slc1a2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001854" MajorTopicYN="N">Bone Marrow Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016026" MajorTopicYN="N">Bone Marrow Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D027342" MajorTopicYN="N">Excitatory Amino Acid Transporter 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="Y">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016086" MajorTopicYN="N">Lentivirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34140581</ArticleId><ArticleId IdType="pmc">PMC8211665</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-92285-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-92285-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure: Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert. Opin. Pharmacother. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Acsadi G, et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum. Gene Ther. 2002;13:1047&#x2013;1059. doi: 10.1089/104303402753812458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104303402753812458</ArticleId><ArticleId IdType="pubmed">12067438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Funakoshi H, Nakamura T. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. J. Neurosci. 2002;22:6537&#x2013;6548. doi: 10.1523/JNEUROSCI.22-15-06537.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-15-06537.2002</ArticleId><ArticleId IdType="pmc">PMC6758174</ArticleId><ArticleId IdType="pubmed">12151533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839&#x2013;842. doi: 10.1126/science.1086137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pubmed">12907804</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes NA, et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J. Clin. Invest. 2010;120:3673&#x2013;3679. doi: 10.1172/JCI42986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI42986</ArticleId><ArticleId IdType="pmc">PMC2947232</ArticleId><ArticleId IdType="pubmed">20890041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TW, Oppenheim RW. Motor neuron trophic factors: therapeutic use in ALS? Brain Res. Rev. 2011;67:1&#x2013;39. doi: 10.1016/j.brainresrev.2010.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2010.10.003</ArticleId><ArticleId IdType="pmc">PMC3109102</ArticleId><ArticleId IdType="pubmed">20971133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KS, Sakowski SA, Feldman EL. Intraspinal stem cell transplantation for amyotrophic lateral sclerosis. Ann. Neurol. 2016;79:342&#x2013;353. doi: 10.1002/ana.24584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24584</ArticleId><ArticleId IdType="pmc">PMC4789073</ArticleId><ArticleId IdType="pubmed">26696091</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Long-term phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 2018;5:730&#x2013;740. doi: 10.1002/acn3.567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.567</ArticleId><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Abati E, Bresolin N, Comi GP, Corti S. Preconditioning and cellular engineering to increase the survival of transplanted neural stem cells for motor neuron disease therapy. Mol. Neurobiol. 2019;56:3356&#x2013;3367. doi: 10.1007/s12035-018-1305-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1305-4</ArticleId><ArticleId IdType="pubmed">30120734</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BL. The use of mesenchymal stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy: A perspective on cell biological mechanisms. Rev. Neurosci. 2017;28:725&#x2013;738. doi: 10.1515/revneuro-2017-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/revneuro-2017-0018</ArticleId><ArticleId IdType="pubmed">28599400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model. Cell. Transplant. 2014;23:1585&#x2013;1597. doi: 10.3727/096368913X673450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368913X673450</ArticleId><ArticleId IdType="pubmed">24070071</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312:1389&#x2013;1392. doi: 10.1126/science.1123511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1123511</ArticleId><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008;11:251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 2005;18:315&#x2013;321. doi: 10.1097/01.wco.0000169752.54191.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.wco.0000169752.54191.97</ArticleId><ArticleId IdType="pubmed">15891419</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. 2004;55:221&#x2013;235. doi: 10.1002/ana.10805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10805</ArticleId><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Siklos L, Appel SH. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 2006;31:427&#x2013;437. doi: 10.1016/j.mcn.2005.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.10.016</ArticleId><ArticleId IdType="pubmed">16337133</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti S, et al. Wild-type bone marrow cells ameliorate the phenotype of SOD1-G93A ALS mice and contribute to CNS, heart and skeletal muscle tissues. Brain. 2004;127:2518&#x2013;2532. doi: 10.1093/brain/awh273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh273</ArticleId><ArticleId IdType="pubmed">15469951</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima T, et al. Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration. J. Neurosci. Res. 2014;92:856&#x2013;869. doi: 10.1002/jnr.23368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23368</ArticleId><ArticleId IdType="pmc">PMC4061499</ArticleId><ArticleId IdType="pubmed">24936617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, et al. The glutamate transporter GLT1a is expressed in excitatory axon terminals of mature hippocampal neurons. J. Neurosci. 2004;24:1136&#x2013;1148. doi: 10.1523/JNEUROSCI.1586-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1586-03.2004</ArticleId><ArticleId IdType="pmc">PMC2849838</ArticleId><ArticleId IdType="pubmed">14762132</ArticleId></ArticleIdList></Reference><Reference><Citation>Furness DN, et al. A quantitative assessment of glutamate uptake into hippocampal synaptic terminals and astrocytes: New insights into a neuronal role for excitatory amino acid transporter 2 (EAAT2) Neuroscience. 2008;157:80&#x2013;94. doi: 10.1016/j.neuroscience.2008.08.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.08.043</ArticleId><ArticleId IdType="pmc">PMC2775085</ArticleId><ArticleId IdType="pubmed">18805467</ArticleId></ArticleIdList></Reference><Reference><Citation>Petr GT, et al. Conditional deletion of the glutamate transporter GLT-1 reveals that astrocytic GLT-1 protects against fatal epilepsy while neuronal GLT-1 contributes significantly to glutamate uptake into synaptosomes. J. Neurosci. 2015;35:5187&#x2013;5201. doi: 10.1523/JNEUROSCI.4255-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4255-14.2015</ArticleId><ArticleId IdType="pmc">PMC4380995</ArticleId><ArticleId IdType="pubmed">25834045</ArticleId></ArticleIdList></Reference><Reference><Citation>Estrada-Sanchez AM, Montiel T, Segovia J, Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol. Dis. 2009;34:78&#x2013;86. doi: 10.1016/j.nbd.2008.12.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.12.017</ArticleId><ArticleId IdType="pubmed">19168136</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob CP, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J. Alzheimers Dis. 2007;11:97&#x2013;116. doi: 10.3233/jad-2007-11113.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-2007-11113</ArticleId><ArticleId IdType="pubmed">17361039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chotibut T, et al. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. Mov. Disord. 2017;32:1547&#x2013;1556. doi: 10.1002/mds.27077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27077</ArticleId><ArticleId IdType="pmc">PMC5681381</ArticleId><ArticleId IdType="pubmed">28631864</ArticleId></ArticleIdList></Reference><Reference><Citation>Proper EA, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain. 2002;125:32&#x2013;43. doi: 10.1093/brain/awf001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awf001</ArticleId><ArticleId IdType="pubmed">11834591</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson AR, Binder DK. Post-translational regulation of GLT-1 in neurological diseases and its potential as an effective therapeutic target. Front. Mol. Neurosci. 2019;12:164. doi: 10.3389/fnmol.2019.00164.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2019.00164</ArticleId><ArticleId IdType="pmc">PMC6629900</ArticleId><ArticleId IdType="pubmed">31338020</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond L, et al. A Metadata analysis of oxidative stress etiology in preclinical amyotrophic lateral sclerosis: Benefits of antioxidant therapy. Front. Neurosci. 2018;12:10. doi: 10.3389/fnins.2018.00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00010</ArticleId><ArticleId IdType="pmc">PMC5787557</ArticleId><ArticleId IdType="pubmed">29416499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, et al. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunn JS, Sakowski SA, Feldman EL. Concise review: Stem cell therapies for amyotrophic lateral sclerosis: Recent advances and prospects for the future. Stem Cells. 2014;32:1099&#x2013;1109. doi: 10.1002/stem.1628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1628</ArticleId><ArticleId IdType="pmc">PMC4225704</ArticleId><ArticleId IdType="pubmed">24448926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciervo Y, Ning K, Jun X, Shaw PJ, Mead RJ. Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis. Mol. Neurodegener. 2017;12:85. doi: 10.1186/s13024-017-0227-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-017-0227-3</ArticleId><ArticleId IdType="pmc">PMC5683324</ArticleId><ArticleId IdType="pubmed">29132389</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253&#x2013;263. doi: 10.1016/S1474-4422(11)70015-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70015-1</ArticleId><ArticleId IdType="pubmed">21349440</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, et al. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp. Neurobiol. 2016;25:233&#x2013;240. doi: 10.5607/en.2016.25.5.233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2016.25.5.233</ArticleId><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772. doi: 10.1083/jcb.200908164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200908164</ArticleId><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl. Neurodegener. 2012;1:9. doi: 10.1186/2047-9158-1-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-9158-1-9</ArticleId><ArticleId IdType="pmc">PMC3514090</ArticleId><ArticleId IdType="pubmed">23210447</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch MA. The multifaceted profile of activated microglia. Mol. Neurobiol. 2009;40:139&#x2013;156. doi: 10.1007/s12035-009-8077-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-009-8077-9</ArticleId><ArticleId IdType="pubmed">19629762</ArticleId></ArticleIdList></Reference><Reference><Citation>Huleihel L, et al. Macrophage phenotype in response to ECM bioscaffolds. Semin. Immunol. 2017;29:2&#x2013;13. doi: 10.1016/j.smim.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2017.04.004</ArticleId><ArticleId IdType="pmc">PMC5612880</ArticleId><ArticleId IdType="pubmed">28736160</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassivaro F, et al. Convergence between microglia and peripheral macrophages phenotype during development and neuroinflammation. J. Neurosci. 2020;40:784&#x2013;795. doi: 10.1523/JNEUROSCI.1523-19.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1523-19.2019</ArticleId><ArticleId IdType="pmc">PMC6975289</ArticleId><ArticleId IdType="pubmed">31818979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, et al. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. Nat. Neurosci. 2018;21:541&#x2013;551. doi: 10.1038/s41593-018-0100-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0100-x</ArticleId><ArticleId IdType="pubmed">29507414</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, et al. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol. Neurobiol. 2017;54:7567&#x2013;7584. doi: 10.1007/s12035-016-0245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0245-0</ArticleId><ArticleId IdType="pubmed">27830532</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D, Vaz AR. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell Neurosci. 2014;8:117. doi: 10.3389/fncel.2014.00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00117</ArticleId><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference><Reference><Citation>Geloso MC, et al. The dual role of microglia in ALS: Mechanisms and therapeutic approaches. Front. Aging Neurosci. 2017;9:242. doi: 10.3389/fnagi.2017.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00242</ArticleId><ArticleId IdType="pmc">PMC5524666</ArticleId><ArticleId IdType="pubmed">28790913</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C, Zhang Y, Dong Y. Acute and subacute IL-1beta administrations differentially modulate neuroimmune and neurotrophic systems: possible implications for neuroprotection and neurodegeneration. J. Neuroinflamm. 2013;10:59. doi: 10.1186/1742-2094-10-59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-59</ArticleId><ArticleId IdType="pmc">PMC3656796</ArticleId><ArticleId IdType="pubmed">23651534</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepe G, et al. Selective proliferative response of microglia to alternative polarization signals. J. Neuroinflamm. 2017;14:236. doi: 10.1186/s12974-017-1011-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-1011-6</ArticleId><ArticleId IdType="pmc">PMC5715534</ArticleId><ArticleId IdType="pubmed">29202771</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Zhao K, Ruan Q, Meng C, Yin F. Bone marrow mesenchymal stem cell-derived exosomal microRNA-124-3p attenuates neurological damage in spinal cord ischemia-reperfusion injury by downregulating Ern1 and promoting M2 macrophage polarization. Arthritis Res. Ther. 2020;22:75. doi: 10.1186/s13075-020-2146-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-2146-x</ArticleId><ArticleId IdType="pmc">PMC7146970</ArticleId><ArticleId IdType="pubmed">32272965</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C, et al. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 2018;9:250. doi: 10.1038/s41419-018-0288-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0288-4</ArticleId><ArticleId IdType="pmc">PMC5833860</ArticleId><ArticleId IdType="pubmed">29445154</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675&#x2013;686. doi: 10.1016/s0896-6273(00)80086-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0896-6273(00)80086-0</ArticleId><ArticleId IdType="pubmed">8785064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong Q, et al. Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J. Clin. Invest. 2014;124:1255&#x2013;1267. doi: 10.1172/JCI66163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI66163</ArticleId><ArticleId IdType="pmc">PMC3938250</ArticleId><ArticleId IdType="pubmed">24569372</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw PJ, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: Elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4:209&#x2013;216. doi: 10.1006/neur.1995.0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1995.0026</ArticleId><ArticleId IdType="pubmed">7583686</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser HW. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy. Brain. 1997;120(Pt 8):1485&#x2013;1508. doi: 10.1093/brain/120.8.1485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.8.1485</ArticleId><ArticleId IdType="pubmed">9278636</ArticleId></ArticleIdList></Reference><Reference><Citation>Eichler F, et al. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N. Engl. J. Med. 2017;377:1630&#x2013;1638. doi: 10.1056/NEJMoa1700554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1700554</ArticleId><ArticleId IdType="pmc">PMC5708849</ArticleId><ArticleId IdType="pubmed">28976817</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat. Neurosci. 2020;23:1339&#x2013;1351. doi: 10.1038/s41593-020-00718-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00718-z</ArticleId><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008;71:1326&#x2013;1334. doi: 10.1212/01.wnl.0000327668.43541.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000327668.43541.22</ArticleId><ArticleId IdType="pubmed">18936424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa N, et al. Gene therapy for neuropathic pain by silencing of TNF-alpha expression with lentiviral vectors targeting the dorsal root ganglion in mice. PLoS ONE. 2014;9:e92073. doi: 10.1371/journal.pone.0092073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092073</ArticleId><ArticleId IdType="pmc">PMC3958473</ArticleId><ArticleId IdType="pubmed">24642694</ArticleId></ArticleIdList></Reference><Reference><Citation>Terashima T, et al. Enhancing the therapeutic efficacy of bone marrow-derived mononuclear cells with growth factor-expressing mesenchymal stem cells for ALS in mice. iScience. 2020;23:101764. doi: 10.1016/j.isci.2020.101764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101764</ArticleId><ArticleId IdType="pmc">PMC7677706</ArticleId><ArticleId IdType="pubmed">33251493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>